© 2018 Miraculo Inc. All Rights Reserved
Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection
Cannabinoids are a group of chemicals that come from the cannabis plant (cannabis sativa). Cannabidiol (CBD) is one of these chemicals and studies have suggest that it has anti inflammatory effects when induced in animals. Tetrahydrocannabinol (THC) is another one of these compounds that wields a psychotropic effect in animals. Cannabinoid receptors (CB1 and CB2) are found in the endocannabinoid system and allow cannabinoids to bind and do their job in the body. This paper will look at how cannabis based products can be therapeutic for parkinson’s disease and what neuroprotective effects cannabis has on the brain.
Cannabinoids can help alleviate symptoms of PD
Parkinson’s disease (PD) is a slow moving neurological syndrome described by a loss of dopaminergic neurons in the hippocampus region of the brain. Although numerous current test developments have suggested a treatment to PD, there isn’t really any clinically existing treatment for its cure. More and more results are indicating a prominent modulatory ability of the cannabinoid transmissioning system in the basal ganglia. Hence, application of cannabinoids as a new therapeutic site has been suggested as a potentially good therapy for PD. The parts of the endocannabinoid system are highly displayed in the neural circuit of basal ganglia where a relationship is shared by dopaminergic, glutamatergic, and GABAergic transmissioning systems. Cannabinoid agonists such as WIN-55,212-2 have been seen in tests as having neuroprotective properties in PD, with regard to their function to stop excitotoxicity, glial triggering, and oxidative damage that causes degeneration of dopaminergic neurons. This paper has tried to find further lines of study that help with the accumulation of knowledge to better the understanding of the therapeutic benefits the cannabinoid systems has for treating PD.
Cannabinoids can be therapeutic in the treatment of PD
Plenty of studies have supported the fact that massive changes of the cannabinoid transmissioning system happens in PD. This conception has been backed up by different electrophysiological, anatomical, and pharmacological discoveries. Therefore, pharmacological changing of this system with chemicals that specifically target separate parts of cannabinoid transmissioning might better anomalies of motor behavior and give a home for neuroprotection. The antioxidant actions of certain cannabinoid chemical compounds, which are independent of their cannabinoid receptor role also have a possibility to be advanced as a treatment for PD.s13024-015-0012-0